Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $39.18 and last traded at $39.13, with a volume of 3433 shares changing hands. The stock had previously closed at $37.15.
Wall Street Analysts Forecast Growth
Separately, JPMorgan Chase & Co. began coverage on Ascentage Pharma Group International in a report on Thursday, March 27th. They issued an "overweight" rating for the company.
Get Our Latest Stock Analysis on AAPG
Ascentage Pharma Group International Trading Down 4.4%
The company's fifty day moving average is $27.46. The company has a debt-to-equity ratio of 3.24, a quick ratio of 1.26 and a current ratio of 1.26.
Hedge Funds Weigh In On Ascentage Pharma Group International
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International as of its most recent filing with the Securities & Exchange Commission.
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
